Initially used methotrexate single drug treatment curative effect prediction model and application
The invention discloses a methotrexate initial single-drug treatment effect prediction model, a construction method and application thereof, and belongs to the field of bioinformatics analysis. Independent factors related to the therapeutic effect of methotrexate are determined by applying logistic regression, including younger age at diagnosis, closer treatment age, independent upper gastrointestinal diseases (only for CD), and longer interval time from diagnosis to start of use of methotrexate (for UC). And a nomogram is established to effectively predict the risk of one-year, three-year and five-year surgery of CD and UC patients initially receiving methotrexate single-drug treatment. According to the method, a precise prediction model is provided for clinical application of methotrexate initial single-drug treatment, patients ineffective in treatment are prevented from suffering from unnecessary side effect risks, patients with high surgical risks are maximized from early surgery as much as possible, and the method has great clinical significance..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 27. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SANG LIXUAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-12-27, Last update posted on www.tib.eu: 2023-06-29, Last updated: 2023-07-08 |
|---|
| Patentnummer: |
CN115527682 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016351703 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016351703 | ||
| 003 | DE-627 | ||
| 005 | 20230708145451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016351703 | ||
| 035 | |a (EPA)CN115527682 | ||
| 035 | |a (EPA)84699085 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SANG LIXUAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Initially used methotrexate single drug treatment curative effect prediction model and application |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-12-27, Last update posted on www.tib.eu: 2023-06-29, Last updated: 2023-07-08 | ||
| 520 | |a The invention discloses a methotrexate initial single-drug treatment effect prediction model, a construction method and application thereof, and belongs to the field of bioinformatics analysis. Independent factors related to the therapeutic effect of methotrexate are determined by applying logistic regression, including younger age at diagnosis, closer treatment age, independent upper gastrointestinal diseases (only for CD), and longer interval time from diagnosis to start of use of methotrexate (for UC). And a nomogram is established to effectively predict the risk of one-year, three-year and five-year surgery of CD and UC patients initially receiving methotrexate single-drug treatment. According to the method, a precise prediction model is provided for clinical application of methotrexate initial single-drug treatment, patients ineffective in treatment are prevented from suffering from unnecessary side effect risks, patients with high surgical risks are maximized from early surgery as much as possible, and the method has great clinical significance. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G16H: Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WANG MENGYAO |4 aut | |
| 700 | 0 | |a CHANG BING |4 aut | |
| 700 | 0 | |a LI QUANSHENG |4 aut | |
| 700 | 0 | |a WEI QINGYU |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 27. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:27 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84699085/publication/CN115527682A1?q=CN115527682 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 27 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 27 |c 12 | ||